STOCKS TELEGRAPH

Author: Shariq Khan

  • Volcon, Inc. (VLCN) declined in the current market; here is why?

    Volcon, Inc. (VLCN) declined in the current market; here is why?

    The stock of Volcon, Inc. (VLCN) declined in the current market after the company announced its underwritten public offering. VLCN values at around $2.90, losing more than 23% from the previously closed value. At the end of the last trading session, the stock closed at around $3.78. The stock volume traded in the last trading session was around 150.78K shares.

    The reason for the stock decline

    Volcon, Inc. (VLCN) announced today the pricing of an underwritten public offering of 6,666,667 shares of common stock, par value $0.00001 per share, at a public price of $3.0 per share. The offering was made in connection with the company’s acquisition of Volcon, Inc. Before underwriting discounts and commissions, as well as anticipated Offering expenditures; the company anticipates total proceeds of approximately $20.0 million.

    If the underwriter exercises its 45-day option to purchase up to an additional 1,000,000 shares of Common Stock, the total gross proceeds from the Offering will be approximately $23 million, according to the underwriter’s estimates. Aegis Capital Corporation is the sole book-running manager for the Offering. On February 1, 2022, the business estimates that VLCN will complete the deal will all the criterila fulfilled

    Under an effective registration statement on Form S-1 (No. 333-262343) filed with the Securities and Exchange Commission or SEC on January 28, 2022, Volcon, Inc. makes the securities described above available to the public. The final prospectus will be filed with the Securities and Exchange Commission and made available on the Commission’s website.

    Effect on the stock

    The stock of Volcon, Inc. (VLCN) fell when the firm stated that it would be liquidating its equities. The company’s stock is declining due to this reason the investors are hesitant to invest in it.

    Conclusion

    Following the announcement of Volcon, Inc.’s (VLCN) underwritten public offering, the shares plummeted in the stock market. The net proceedings from the public offering, which totaled $20 million, the company will use it for working capital, general corporate expenses, administrative expenses, and sales and marketing.

  • Atlassian Corporation Plc (TEAM) stock gained early Friday; here is why?

    Atlassian Corporation Plc (TEAM) stock gained early Friday; here is why?

    Atlassian Corporation Plc (TEAM) stock gained in the current market after the company announced its results for the second quarter of 2022. The stock of TEAM values at around $308, gaining more than 6% from the previously closed value. The company’s stock closed at $290 in the previously closed session. The stock volume traded in the last trading session was around 2.2 million.

    Reasons for the stock gain

    • Atlassian Corporation Plc (TEAM) announced revenue of $688.5 million for the second quarter of fiscal 2022. In the second quarter of fiscal 2021, the revenue was around $501.4 million. The increase in the revenue was around 37%.
    • Atlassian Corporation Plc (TEAM) reported an operating loss of $66.7 million in Q2 2022. In Q2 of 2021, the company reported an operating income of $27.7 million.
    • In Q2 of 2022, the operating margin is (10%, while last year, in the same period, it was 6%.
    • Net loss of Atlassian Corporation Plc (TEAM) was around $77.5 million in Q2 2022. Last year in the same quarter, the net loss was $621.5 million.
    • As of the second quarter of 2022, Atlassian Corporation Plc (TEAM) has cash and cash equivalents of $986 million.
    • The cash flow from operation was around $222 million in the second quarter of 2022. The free cash flows were around $197.

    The effect on the stock

    As soon as the company announced its results for the second quarter, its stock surged due to the positive numbers. Investors are responding positively to the reports. Although the second quarter was not profitable, its revenue grew by 37%. It shows the company is growing and will be profitable when then achieve their targeted market share.

    Conclusion

    Atlassian Corporation Plc (TEAM) expects revenue between $690 million to $705. The company is focusing on increasing its revenue and adding new customers to its business. Once they achieve their desired market share, they will become profitable.

  • Danimer Scientific, Inc. (DNMR) gained in the pre-market; here is why?

    Danimer Scientific, Inc. (DNMR) stock gained in the pre-market after the company announced its agreement with Hyundai Oilband in a press release. DNMR values at $4.60, gaining more than 1.7% from the previously closed value. At the end of the last trading session, the stock closed at $4.86. The stock volume traded in the last trading session was around 4.5 million shares.

    Reason for the stock gain

    Danimer Scientific, Inc. (DNMR) announced today that it has agreed with Hyundai Oilbank, a subsidiary of Hyundai Heavy Industries Holdings, to collaboratively develop global new markets and applications for polyhydroxyalkanoate (PHA), a biodegradable alternative to traditional plastic.

    This collaboration will first focus on supplying Nodax, Danimer’s flagship PHA, and other PHA-based compounds to business clients in South Korea and other Asian markets for ecological single-use packaging. The firms hope to expand worldwide PHA manufacturing potential.

    According to the company, a global response is required to reduce the environmental impact of plastic trash. Meanwhile, they are excited to join with one of South Korea’s most influential corporate leaders, Hyundai Oilbank, to offer our sustainable materials and encourage the growth of PHA applications across Asia.

    Although the considerable environmental damage caused by the burning and recovery of discarded plastics, plastic consumption keeps rising. By replacing typical plastics with biodegradable polymers, the firm can reduce pollution and is thrilled to engage with Danimer Scientific on this vital and transformative endeavor.

    Reason for the stock gain

    The stock gained in the pre-market due to its significant agreement with Hyundai Oilbank. This strategic partnership could be an excellent opportunity to enhance its business.

    Conclusion

    The bioplastic company is keen to implement its vision of biodegradable products. The company should benefit from the deal to grow itself and achieve its goals.

  • Accuray Incorporated (ARAY) gained in the Afterhours, here is why?

    Accuray Incorporated (ARAY) stock gained in the after-hours trading session when the company announced its results for the second quarter of 2022. ARAY values at $4.35, gaining more than 7% from the previously closed value. At the end of the last trading session, the stock closed at around $4.10. The stock volume traded in the last trading session was around 780.47K shares.

    Highlights of Q2 2022

    Accuray Incorporated’s (ARAY) revenue in the second quarter of 2022 is $116.3 million. The revenue for the same period in 2021 was around $97.5 million.

    Accuray Incorporated (ARAY) reported a gross profit of $42.6 million in Q2 2022. It is around 36.7% of the revenue. The gross profit for the same period in 2021 was $40.8 million or 41.9%.

    The operating expenses in Q2 2022 are $38.6 million. It is a gain of more than 18% from the same period of 2021. Previously operating expenses were $32.6 million.

    Accuray Incorporated (ARAY) reported a net income of $0.2 million Q2 2022. In Q2 2021, the company’s net income was $4.8 million.

    As of the second quarter of 2022, Accuray Incorporated (ARAY) has around $123.4 million in cash and cash equivalents.

    Highlights of the first half of 2022

    Accuray Incorporated’s (ARAY) revenue in the first half of 2022 is $223.7 million. The revenue for the same period in 2021 was around $182.8 million.

    Accuray Incorporated (ARAY) reported a gross profit of $82.2 million in the first half of 2022. It is around 36.7% of the revenue. The gross profit for the same period in 2021 was $76.2 million, or 41.7%.

    The operating expenses in the first half of 2022 are $75.8 million. It is a gain of more than 21% from the same period of 2021. Previously operating expenses were $62.6 million.

    Accuray Incorporated (ARAY) reported a net income of $0.8 million first half of 2022. In the first half of 2021, the company’s net income was $5.2 million.

    The effect on the stock

    Investors are responding positively to the results of the company’s second-quarter results. The after-hours market is volatile as most investors prefer to trade in the regular trading session.

    Conclusion

    The outlook of the company seems promising. The company aims to achieve a revenue goal of $420 million to $430 million.

  • Document Security Systems, Inc. (DSS) declined in the current market; here is why?

    The stock of Document Security Systems, Inc. (DSS) declined in the current market after the company announced its common stock issue for purchase to Alset EHome International, Inc. (AEI). DSS values at around $0.37, losing more than 9.84% from the previously closed value. At the end of the previous trading session, the stock closed at $0.41. The stock traded volume in the last trading session was around 909.08K shares.

    Reason for the stock decline

    As part of the deal, Document Security Systems agreed to issue up to 44,619,423 shares of common stock to Alset EHome International, Inc. (AEI) for a purchase price of $0.3810 per share. According to the NYSE American, LLC regulations and laws, the Company’s shareholders will have to give their consent before any new shares are issued.

    Alset EHome International, the firm’s principal stakeholder, has shown high confidence in the enterprise, according to the company. Due to the additional strength that our balance sheet has gained as a result of this newest cash infusion, we will be able to quickly capitalize on the plethora of possibilities across our different business lines.

    A previous couple of years has seen us work relentlessly to lay the groundwork for long-term wealth generation for our stockholders. According to the corporation, this approach is now entering its second phase, which will exploit this base to enhance revenue growth and eventually push bottom-line success.

    The effect on the stock

    The deal will result in some equity purchase of DSS by Alset EHome International, Inc. (AEI). Its stock might increase after the deal if the net proceedings gained from the deal are used correctly by Document Security Systems.

    Conclusion

    Document Security Systems, Inc. (DSS) stock is currently less than $1. To continue, they must value more than $1.00 per share. That is why they might have offered the common stock purchase agreement to AEI to use the net proceedings as working capital.

  • Stride, Inc. (LRN) surged in the current market; here is what you need to know.

    Stride, Inc. (LRN) surged in the current market; here is what you need to know.

    Stride, Inc. (LRN) skyrocketed in the current market after the company announced its results for the second quarter of 2022. LRN values at around $34.90, gaining more than 30% from the previously closed value. At the end of the last trading session, the stock closed at around $27.01. The stock traded volume in the previous trading session was approximately 392.06K shares.

    Highlights of second quarter 2022

    • The revenue of Stride, Inc. (LRN) was $409.5 million in the second quarter of 2022 compared to the 2nd quarter of 2021, when the revenue was $376.1 million.
    • The operating income in the second quarter is $56.9 million. Operating income in the same period in 2021 was $38.5 million. Operating income gained from the cut on the administrative expenses and improved gross margin.
    • Stride, Inc. (LRN) reports a net income of $42 million. Net income in Q2, 2021 was around $24.5 million.
    • As of the second quarter of 2022, Stride, Inc. (LRN) had cash and cash equivalents of $257 million.

    Highlights of first six months of fiscal 2022

    • The revenue of Stride, Inc. (LRN) is $809.7 million in the first half of 2022 as compared to the first half of 2021 when the revenue was $747.1 million.
    • The operating income in the first half is $49.9 million. Operating income in the same period in 2021 was $50.5 million.
    • Stride, Inc. (LRN) reports a net income of $36.1 million in the first half. Net income in the first half was around $37.2 million.

    The effect on the stock

    The stock of Stride, Inc. (LRN) gained significantly in the current market as soon as its results got public. Investors responded positively to the favorable numbers reported by Stride, Inc. (LRN). Its stock was

    Conclusion

    Stride, Inc. (LRN) outlook of the fiscal year seems promising. They are targeting revenue between $1.62 billion and $1.64 billion. The company’s growth rate is impressive in the second quarter of 2022, and with the same growth rate, it can achieve its forecasted revenue for fiscal 2022.

  • Mainz Biomed B.V. (MYNZ) declined in the current market; here is why?

    Mainz Biomed B.V. (MYNZ) declined in the current market; here is why?

    The stock of Mainz Biomed B.V. (MYNZ) declined in the current market after Mainz announced its underwritten public offering in a press release. MYNZ values at around $15.44, losing more than 23% from the previously closed value. At the end of the last trading session, the stock closed at around $20.25. The stock volume traded in the previous trading session was around 966.23K shares.

    Reason for the stock decline

    Mainz Biomed B.V. (MYNZ) announced a follow-on public offering of 1,500,000 ordinary shares for $15.00 per common stock netting $22,500,000.

    According to a registration declaration on Form F-1 filed with the SEC, the Follow-On Offering is offered. The Follow-On Offering expects to end on January 28, 2022, if all regular closing terms are fulfilled. In connection with the Follow-On Offering, Mainz Biomed has granted an underwriter the option to purchase up to 225,000 extra common stock at the Purchase Price to mitigate any over-allotments. Mainz Biomed is selling all of the shares.

    Boustead Securities, LLC is the only underwriter for the offering. Mainz Biomed hired Ortoli Rosenstadt LLP as its lawyer. Sichenzia, Ross and Ference LLP represented the underwriter.

    The prospectus is the exclusive medium for the offering. Boustead Securities, LLC will make the final prospectus available when it becomes available.

    Effect on the stock

    The news hit the market in Pre-market hours. Pre-market is a bit volatile as most traders prefer to trade in the regular trading session. The regular trading has just begun, and investors can assess actual effect of the offering at the end of the current session. In such cases, the stock price most of the time remains low when the session closes.

    Conclusion

    The company is looking forward to using the money in general administrative expenses and working capital. They might use the money in sales marketing to achieve fiscal 2022.

  • Microsoft Corporation (MSFT) gained in the after-hours; here is why?

    Microsoft Corporation (MSFT) gained in the after-market following its announcement of results for the second quarter of fiscal 2022. MSFT stock values at $292, gaining more than 1.22% from the previously closed value. At the end of the last trading session, the stock closed at around $288.49. The stock volume traded in the previous trading session was around 34.90 million shares.

    Highlights of Q2 2022

    • Microsoft Corporation (MSFT) reported $51.7 billion in sales, a 20 percent gain compared to Q2 of 2021.
    • Microsoft reports an operating income of $22.2 billion, showing a 24% gain over the Q2 of 2021.
    • Net income was $18.8 billion, demonstrating a 21% raise over the Q2 of 2021.
    • The diluted earnings per share are $2.48, shows a 22% gain compared to Q2 of 2021.
    • According to Microsoft, solid marketing, as evidenced by bookings led by long-run Azure contracts, helped Microsoft Cloud sales climb to $22.1 billion, a 32% gain.
    • Processes generated sales of $15.9 billion, showing a 19% gain over the previous year.
    • Intelligent Cloud sales were $18.3 billion, showing a 26% growth.
    • Personal computing gained $17.5 billion in sales, indicating a 15% gain.
    • In the second quarter of the fiscal year 2022, Microsoft repaid $10.9 billion to shareholders in the form of share repurchases and dividends, indicating a 9% increase over the same period in the fiscal year 2021.

    The effect on the stock gain

    As soon as Microsoft announced its results for the quarter of 2022, its stock surged. Investors responded positively to the numbers and significant business developments in Q2 of 2022.

    Conclusion

    Microsoft will soon announce the outlook for 2022. But its increased revenue from cloud-based services is the hook that could make the investors not to ignore its stock. Cloud services are in tremendous demand, and its massive increase in this segment of its business seems promising.

  • Texas Instruments Incorporated (TXN) gained in the after-hours, here’s why?

    Texas Instruments Incorporated (TXN) stock gained in the after-hours following its announcement of results for the fourth quarter and fiscal 2021. The stock of TXN values at around $180, gaining more than 3.7% from the previously closed value. At the end of the last trading session, the stock closed at $173.96. The stock volume traded in the last trading session was around 5.35 million shares.

    Highlights of the results

    • The revenue of Q4 2021 is $4.832 billion. It is an increase of 19% from Q4 2020. The revenue in Q4 2020 was $4.076 billion. The revenue of fiscal 2021 is $18.344 billion. It is an increase of 26% from fiscal 2020. The revenue in fiscal 2020 was $14.461 billion.
    • The net income of Q4 2021 is $2.138 billion. It is an increase of 27% from the net income of Q4 2020. The net income in Q4 2020 was $1.688 billion. The company reports a net income of $7.769 in fiscal 2021. The net income in fiscal 2020 was $5.595 billion.
    • The company’s cash flow from operations for 2021 is $8.8 billion. Free cash flow totaled $6.3 billion during the year, accounting for 34% of total sales.
    • In 2021, the business will return $4.4 billion to shareholders through dividends and stock repurchases. Their payout equaled 62 percent of free cash flow for the year.
    • TI expects sales in the range of $4.50 billion to $4.90 billion and profits per share in the range of $2.01 to $2.29 for the first quarter of fiscal 2019. TI anticipates that its annual operating tax rate will be approximately 14 percent in 2022.
    • As of fiscal 2021, the company has around $4.631 billion cash equivalents.

    Effect on the stock

    The stock of the company soared following the news of its quarterly results. Investors seem to be impressed by the numbers and are interested in investing in its stock.

    Conclusion

    The company’s outlook seems promising, and they are expecting to keep the growth rate consistent. In the first quarter, they expect to keep the growth rate the same as in the Q4 of 2021.

  • Checkpoint Therapeutics, Inc. (CKPT) gained in the current, why?

    Checkpoint Therapeutics, Inc. (CKPT) gained in the current, why?

    Checkpoint Therapeutics, Inc. (CKPT) gained in the current market after announcing positive results for its trials. The stock of CKPT values at $2.40 in the current market, gaining more than 10% from the previously closed value. At the end of the last trading session, the stock closed at around $2.19. The stock volume traded in the last trading session was around 877.95K shares.

    The reason for the stock gain

    Checkpoint Therapeutics, Inc. (CKPT) announced positive results from the clinical trial in a press release. A restricted dose of 800 mg every two weeks of cosibelimab, Checkpoint Therapeutics’ anti-PD-L1 antibody, was provided to patients with metastatic cutaneous squamous cell carcinoma (cSCC) in a registration-enabling clinical trial.

    The research accomplished its fundamental aim, with cosibelimab showing a proven ORR of 47.4% (95 percent CI: 36.0, 59.1) in 78 metastatic cSCC patients using RECIST 1.1 criteria. The DOR was not yet attained (76 percent of ongoing responses). The study’s safety data for 201 advanced cancer patients treated in all cohorts remain consistent, with most treatment-emergent adverse events being grade 1 or 2. After submitting a BLA to the FDA for cosibelimab, Checkpoint plans to apply an MAA to the European Medicines Agency and other global submissions.

    As well as the global, randomized Phase 3 (CONTERNO) trial of cosibelimab in pairing with pemetrexed and platinum chemotherapy for patients with non-squamous non-small cell lung cancer, Checkpoint continues to enlist patients with locally advanced cSCC.

    Effect on the CKPT stock

    Investors are responding positively to the news. CKPT stock showed some positive results from the study. They expect it as a significant revenue source once it gets approval from the FDA. The company also focuses on research on other diseases and expects a good response.

    Conclusion

    CKPT announced some positive results from the study on patients with cSCC treated with anti-PD-L1 antibody. The study shows a 47% response rate, and the company is anticipating achieving better results in the future. They are also planning for a BLA this year.